News Column

Researchers from Tabriz University of Medical Sciences Detail New Studies and Findings in the Area of Pharmaceutical Research (Self-reporter...

July 25, 2014



Researchers from Tabriz University of Medical Sciences Detail New Studies and Findings in the Area of Pharmaceutical Research (Self-reporter shikonin-Act-loaded solid lipid nanoparticle: Formulation, physicochemical characterization and ...)

By a News Reporter-Staff News Editor at Drug Week -- A new study on Drugs and Therapies is now available. According to news reporting from Tabriz, Iran, by NewsRx journalists, research stated, "Shikonin and some of its derivative have approved apoptotic potential in different human cancer cell lines, and moreover have a dominant fluorescent emission at similar to 600 nm. Here, to enhance shikonin-Act anti-proliferation properties, it was successfully incorporated in Solid Lipid Nanoparticles (SLNs) by the hot homogenization and entrapment efficiency (EE) of drug in SLNs was determined by ultrafiltration method."

The news correspondents obtained a quote from the research from the Tabriz University of Medical Sciences, "Scanning electron microscopy (SEM), laser diffractometry and zeta-sizer indicated that shikonin-Act-SLN were spherical and regular particles in the range of 70-120 nm with polydispersity index (PI) of less than 0.10. The physical stability of shikonin-Act-loaded SLN in aqueous dispersion was evaluated in terms of size, PI, EE and drug leakage and the results showed that SLNs were stable upon storing three month. Long term in vitro release of the shikonin-Act was also approved. Cellular uptake of the shikonin-Act-SLN was examined by the in vitro fluorescent microscopy and facs flow cytometry analyses. In vivo rat imaging approved the penetrating capability of shikonin-Act-SLN emission through living tissues. In vitro anti-proliferation and genotoxicity evaluation by MTT and comet assay confirmed that shikonin-Act-SLN showed higher cytotoxic/antitumor potential than intact shikonin in terms of IC50 and DNA damage."

According to the news reporters, the research concluded: "This work provide sufficient information about improving of the therapeutic efficacy of the shikonin-Act, and also using of the shikonin-Act-SLN in bio-distribution studies during drug delivery investigation by incorporating in lipidic and colloidal drug delivery particles such as SLNs."

For more information on this research see: Self-reporter shikonin-Act-loaded solid lipid nanoparticle: Formulation, physicochemical characterization and geno/cytotoxicity evaluation. European Journal of Pharmaceutical Sciences, 2014;59():49-57. European Journal of Pharmaceutical Sciences can be contacted at: Elsevier Science Bv, PO Box 211, 1000 Ae Amsterdam, Netherlands. (Elsevier - www.elsevier.com; European Journal of Pharmaceutical Sciences - www.elsevier.com/wps/product/cws_home/523997)

Our news journalists report that additional information may be obtained by contacting M. Eskandani, Tabriz Univ Med Sci, Fac Pharm, Tabriz, Iran (see also Drugs and Therapies).

Keywords for this news article include: Iran, Asia, Tabriz, Drugs and Therapies

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Drug Week


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters